The winter season ushers in a new globally spreading COVID-19 variant called XEC, a mix of KS.1.1 and KP.3.3, both from the ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older.

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

The European stock markets closed lower in Friday trading as the FTSE in London was down 1.19%, Germany's DAX slipped 1.49%, France's CAC lost 1.51%, the Stoxx Europe 600 fell 1.42% and the Swiss ...

Shares of Trump Media & Technology Group Corp. slumped to their lowest level ever early Friday morning, the first day that ...

The augmented reality (AR) navigation market is expected to reach USD 6.33 billion by 2029 from USD 1.17 billion in 2024, at ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...

The first big update to U.S. methadone regulations in 20 years is poised to expand access to the life-saving drug starting ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...